We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




AI Model Detects Cancer at Lightning Speed through Sugar Analyses

By LabMedica International staff writers
Posted on 04 Jul 2024

Glycans, which are structures made up of sugar molecules within cells, can be analyzed using mass spectrometry. More...

This technique is particularly useful because these sugar structures can reveal the presence of various cancer types within cells. However, interpreting the data from mass spectrometry, specifically, the fragmentation patterns of glycans, requires meticulous human analysis. This detailed scrutiny can take from several hours to days per sample and is only reliably performed by a handful of highly skilled experts globally, as it involves complex, learned detective work over many years. This need for expert analysis creates a significant bottleneck in utilizing glycan analysis for applications like cancer detection, especially when numerous samples need examination. Researchers have now introduced an artificial intelligence (AI) model that enhances the ability to detect cancer through sugar molecule analysis, proving to be both quicker and more effective than the traditional semi-manual approaches.

The AI model, named Candycrunch, was trained by researchers at the University of Gothenburg (Gothenburg, Sweden) using a vast database containing over 500,000 examples of various fragmentations and associated structures of sugar molecules. This extensive training has equipped Candycrunch to accurately determine the precise structure of sugars in a sample in 90% of cases, aiming to soon match the accuracy levels seen in the sequencing of other biological sequences like DNA, RNA, and proteins. The AI model described in a scientific article published in Nature Methods automates glycan analysis and completes it in just a few seconds. Moreover, Candycrunch can identify sugar structures that are typically overlooked by human analysts due to their low concentrations. Due to its speed and precision, Candycrunch significantly speeds up the identification of glycan-based biomarkers, which are crucial for diagnosing and predicting cancer. Thus, the model holds promise in aiding researchers to discover new glycan-based biomarkers for cancer.

“We believe that glycan analyses will become a bigger part of biological and clinical research now that we have automated the biggest bottleneck,” said Daniel Bojar, Associate Senior Lecturer in Bioinformatics at the University of Gothenburg.

Related Links:
University of Gothenburg


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.